US 12,331,075 B2
Optimized method for antibody capturing by mixed mode chromatography
Roberto Falkenstein, Munich (DE); Thorsten Lemm, Kochel am See (DE); Markus Strasser, Penzberg (DE); and Hidenari Yamada, Tokyo (JP)
Assigned to Hoffmann-La Roche Inc.
Filed by Hoffmann-La Roche Inc., Nutley, NJ (US)
Filed on Jan. 31, 2020, as Appl. No. 16/778,128.
Application 16/778,128 is a continuation of application No. 16/448,295, filed on Jun. 21, 2019, abandoned.
Application 16/448,295 is a continuation of application No. 15/216,099, filed on Jul. 21, 2016, granted, now 10,377,794, issued on Aug. 13, 2019.
Application 15/216,099 is a continuation of application No. 13/883,243, granted, now 9,422,329, issued on Aug. 23, 2016, previously published as PCT/EP2011/069202, filed on Nov. 2, 2011.
Claims priority of application No. 10190192 (EP), filed on Nov. 5, 2010.
Prior Publication US 2020/0165297 A1, May 28, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 1/18 (2006.01); C07K 16/06 (2006.01); C07K 16/28 (2006.01)
CPC C07K 1/18 (2013.01) [C07K 16/065 (2013.01); C07K 16/2863 (2013.01)] 11 Claims
 
1. A method for producing an anti-IGF-IR antibody comprising the following steps:
a) applying a crude mammalian cell culture cultivation supernatant to a multimodal weak cation exchange chromatography material, and
b) recovering the anti-IGF-IR antibody by applying a buffered solution comprising ethylene glycol and an inorganic salt to the multimodal weak cation exchange chromatography material and thereby producing an anti-IGF-1R antibody
wherein the method does not comprise a protein A affinity chromatography step.